Medical/Pharmaceuticals
Vatech and Pearl Join Forces to Revolutionize Dental Diagnosis with AI Integration
HWASEONG, South Korea, March 18, 2025 /PRNewswire/ -- Vatech, a global leader in dental imaging solutions, and Pearl, a frontrunner in dental AI technology, have announced a collaborative alliance aimed at transforming the landscape of dental diagnosis. By integrating Pearl's advanced AI-powered ...
2025-03-18 21:00
1965
Lunit Secures Multi-Year Contract with UAE's Largest Healthcare Network to Power National AI Breast Cancer Screening Program
Strategic agreement to deploy Lunit INSIGHT MMG across SEHA's extensive healthcare network, analyzing over hundred thousand mammograms over five years SEOUL, South Korea, March 18, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...
2025-03-18 21:00
3141
A chronographic analysis of MSC's rollercoasting journey
TIANJIN, China, March 18, 2025 /PRNewswire/ -- On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking discussions about the historical development of me...
2025-03-18 20:00
2344
So-Young Reschedules Release of Fourth Quarter and Full Year 2024 Financial Results to March 28, 2025
BEIJING, March 18, 2025 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community inChina for consumers, professionals and service providers in the medical aesthetics industry, today announced that it has rescheduled the ...
2025-03-18 17:00
2788
Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension
This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries. TAIPEI, March 18, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipl...
2025-03-18 16:00
3011
TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance thera...
2025-03-18 06:00
1976
Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets
* Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design,...
2025-03-17 21:00
1993
NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR
* Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for treating joint pain, have been published in the est...
2025-03-17 21:00
2388
WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs
* Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year * 2024 Revenue Reached RMB39,241 Million, Up 5.2% Year-over-Year (Excluding COVID-19 Commercial Project of 2023) * Full-Year Net Profit Attributable to the Owners of the Company Reached RMB9,450 Million[1], Diluted Ea...
2025-03-17 20:19
3246
Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies
HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the successful completion of a new round of financing. Heda Health Fund an...
2025-03-17 18:00
2116
Fangzhou Inc.'s H2H Smart Healthcare Platform Honored as one of Guangdong's Premier High-Tech Innovation Products
GUANGZHOU, China, March 17, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, today announced that its proprietary "H2H Smart Healthcare Innovation Platform" has been distinguished as a "2024Guangdong Province Premier High-Qual...
2025-03-17 15:43
1862
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
HONG KONG, March 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasop...
2025-03-17 11:49
2048
Accropeutics Secured $12 Million in Series B Plus Financing
* Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). * Cash runway extended into the second half of 20...
2025-03-14 16:23
2464
MATELASER Introduces X1 Performance: The Ultimate Portable High-Energy Laser Therapy System for Pain Management
MIAMI, March 13, 2025 /PRNewswire/ -- MATELASER, INC., a pioneering force in laser therapy technology, is proud to announce the launch of the X1 Performance, the portable high-energy laser therapy system, designed to meet the highest U.S. medical quality standards for pain management, sports rec...
2025-03-13 22:00
2423
Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation
CAMBRIDGE, Mass., March 13, 2025 /PRNewswire/ -- Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a$110 million Series E financing led by a private equity fund of Value Partners ...
2025-03-13 21:00
3436
Amcor prices private offering of $2.2 billion of senior unsecured notes
ZURICH, March 13, 2025 /PRNewswire/ -- Amcor plc (NYSE:AMCR; ASX:AMC) ("Amcor") announced today that Amcor Flexibles North America, Inc. ("AFNA"), a wholly-owned subsidiary of Amcor, has priced a private offering (the "Offering") of guaranteed senior notes in an aggregate principal amount of$2.2 ...
2025-03-13 18:11
4013
WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025
SHANGHAI, March 13, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, has been honored with...
2025-03-13 13:54
2675
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
SHANGHAI, March 13, 2025 /PRNewswire/ -- BioCity Biopharmaceutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), to evaluate the combination of BioCity's BC3195 ...
2025-03-13 13:17
7889
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
YONGIN, South Korea, March 12, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEOSungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first patient dosing" marks a critical milestone in...
2025-03-13 07:30
2193
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
* STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. * Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA to help...
2025-03-13 07:30
2312
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Philips Evnia x SEGA: Elevating Immersion for YAKUZA KIWAMI 3 & DARK TIES | Unveiling the 27M2N6501L QD-OLED Monitor - Where Speed Meets Spectacle
[Picked up by 260 media titles]
2026-02-12 15:58
Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
8039
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7320
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
6901
